Skip to Content

'
Ricardo H Alvarez, M.D., M.Sc.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman P. Pressler
CPB5.3450
Unit Number: 1354
Houston, TX 77030

Education & Training

Degree-Granting Education

2010 The University of Texas Health Science Center at Houston, Houston, TX, MS, Graduate School of Biomedical Sciences at Houston
1990 Universidad Nacional de La Plata - Facultad de Medicina, Provincia de Buenos Aires, Argentina, MD, Medicine

Postgraduate Training

2008-2010 Master of Science, Cancer Biology, Graduate School of Biomedical Sciences at Houston, Houston, TX
2006-2009 Hem/Onc Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
2004-2006 Resident, Internal Medicine, The University of Texas at Houston, Health Science Center, Houston, TX
1990-1994 Resident, Internal Medicine/Medical Oncology, Centro Oncologico de Excelencia - Gonnet, Provincia de Buenos Aires, Argentina

Board Certifications

9/2009 American Board of Oncology
10/2006 American Board Internal Medicine

Experience/Service

Academic Appointments

Instructor, Oncology Consultants P.A., Houston, TX, 12/1999-6/2003
Assistant Professor and Chief, Oncology Section, Hospital Ramon Carrillo - San Carlos de Bariloche, Rio Negro, Argentina, 6/1996-6/1999
Instructor, Department of Internal Medicine, Universidad Nacional de La Plata, Provincia de Buenos Aires, Argentina, 3/1990-3/1994
Instructor, Department of Pathology, Universidad Nacional de La Plata, Provincia de Buenos Aires, Argentina, 3/1987-3/1992

Honors and Awards

2009 Merit Award, Annual ASCO Meeting
2009 Merit Award, Anti-Angiogenesis Annual Meeting
2008 Award of Excellence in Cancer Research, Texas Medical Society of Oncology
2008 Clinical Fellowship Award, The Susan Papizan Dolan Fellowship in Breast Cancer Research
2008 Merit Award, ASCO Breast Symposium
2008 Merit Award, ASCO-NCI-EORTC Annual Meeting
2006 T-32 NIH CA009666 Ruth L. Kirschstein National Research Service Award, The University of Texas MD Anderson Cancer Center
1996 Special Mention for Best Quality of Research, Municipalidad de La Plata, Argentina

Selected Publications

Peer-Reviewed Original Research Articles

1. Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Bevacizumab Treatment for Advanced Breast Cancer. Oncologist 16(12):1684-97, 2011. e-Pub 10/5/2011. PMID: 21976315.
2. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3):R67, 2011. e-Pub 6/2011. PMCID: PMC3218956.
3. Alvarez RH, Valero V, Hortobagyi GN. Ixabepilone for the treatment of breast cancer. Ann Med 43(6):477-86, 2011. e-Pub 5/17/2011. PMID: 21585248.
4. Alvarez RH, Hortobagyi GN. Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design. Breast Cancer Res Treat 124(3):701-5, 12/2010. PMID: 20953832.
5. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomoy of breast cancer stroma and its prognostic value in ER-positive and - negative cancers. J Clin Onc 28(28):4316-23, 10/2010. PMID: 20805453.
6. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res Suppl 2:S1, Oct 22, 2010, 10/2010. e-Pub 10/2010. PMID: 21050422.
7. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagayi GN, Valero V. Phase II trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiation, and adjuvant chemotherapy with Cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer long-term results from The University of Texas M. D. Anderson Cancer Center study ID97-099. Cancer 116(5):1210-1217, 3/2010.
8. Alvarez RH, Price JE. Biomarkers for breast cancer: the search continues. Cancer Biol Ther 9(1):31-2, 1/2010. e-Pub 1/2010. PMID: 20150755.
9. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Onc 28(20):3366-79, Jul 10, 2010. PMID: 20530283.
10. Alvarez RH, Leone JP, Valero V. Terapia antiangiogenica en el cancer de mama. Revista de Angiogenesis Tumoral, Octubre 2009 1(1):22-32, 10/2009.
11. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 44(Suppl 1):S4-14, 1/2007. PMID: 17292736.
12. Alvarez RH, Kantarjian HM, Cortes JE. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107(8):1918-29, 10/2006. PMID: 16986126.
13. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81(9):1241-57, 9/2006. PMID: 16970222.
14. Cortes JE, O'Brien SM, Giles F, Alvarez RH, Talpaz M, Kantarjian HM. Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am 18(3):619-39, ix, 6/2004. PMID: 15271396.
15. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 50(6):497-500, 12/2002. e-Pub 10/2002. PMID: 12451477.

Abstracts

1. Alvarez RH, Bianchini G, Hsu L, Cristofanilli M, Esteva FJ, Pusztai L, Buzdar AU, Hortobagyi GN, Valero V. Clinical Outcome of Two Sequences of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC). 2010 SABCS, 12/2010.
2. Alvarez RH, Cristofanilli M, Hsu L, Ueno NT, Alizadeh PA, Lucci A, Reuben JM, Buchholz TA, Hortobagyi GN, Valero V. Patient characteristics and clinical outcome of patients with secondary inflammatory breast cancer: MD Anderson Cancer Center, retrospective review. 2010 SABCS, 12/11/2010, 12/2010.
3. Alvarez RH, Albarracin CT, Valero V, Hsu L, Sahin A, Johnson M, Hortobagyi GN, Moulder SL. Discordance rates of HER-2 expression between breast primary tumors and paired metastases using archived tumor specimens. Breast Cancer Symposium, 10/2008.

Book Chapters

1. Alvarez RH, Valero V. In: Targeted Therapy for Breast Cancer, Cancer Etiology, Diagnosis and Treatments. Ed(s) Alfonso-Quintas-Cardama, Don L Gibbons, Vince Cataldo. Nova Science Publishers, Inc. New York, 117-150, 2011. ISBN: 978-1-61761-854-3.

Manuals, Teaching Aids, Other Teaching Publications

1. Alvarez RH, Valero V. Molecular Biology of Breast Cancer and Targeted Therapy. In Press.

Grant & Contract Support

Title: Investigator Initiated Study. A randomized phase II neoadjuvant study of sequential eribuin followed by FAC-regime compared to sequential paclitaxel followed by FAC/FEC-regimen in women with early stage breast cancer not overexpressing HER2
Funding Source: EISAI
Role: Principal Investigator
Duration: 10/2011 - present
 
Title: Investigator Initiated Study. A phase II, open label study of efficacy of TKI258 (Dovitinib lactate) inpatients who have received up to two chemotherapy lines for metastatic HER2-negative Inflammatory. 2010-0296
Funding Source: Novartis
Role: Principal Investigator
Duration: 11/1/2010 - 12/31/2014
 
Title: Prognostic utility of activated tumor markers in circulating tumor cells (CTCs) and in fine needle aspirate (FNAs) of breast cancer patients. LAB10-0229
Funding Source: Prometheus Laboratories Inc
Role: Principal Investigator
Duration: 6/30/2010 - 6/29/2014
 
Title: A Phase II study of combination of ixabepilone plus MLN8237, an aurora kinese inhibitor in breast cancer patients 2009-0827
Funding Source: Millenium
Role: Principal Investigator

Last updated: 7/29/2013